Unlearn, a San Francisco, CA-based provider of machine-learning technology that creates digital twins of patients in clinical trials to enable faster studies, raised $50M in Series B funding.
The round was led by Insight Partners with participation from Radical Ventures, 8VC, DCVC, DCVC Bio and Mubadala Capital Ventures. Through the investment, Dylan Morris, Managing Director, Insight Partners, joined the Unlearn Board of Directors.
The company intends to use the funds to make rapid progress as they expand their work with global biopharmaceutical companies and advance productive conversations with global regulatory authorities who are committed to supporting innovation in clinical trials.
Led by CEO Charles Fisher, Unlearn is a company creating TwinRCTs, which combine AI, digital twins, and novel statistical methods to enable efficient clinical trials.
The company works with pharma sponsors, biotech companies, and academic institutions to optimize human clinical trials with TwinRCTs™. A TwinRCT™ is a randomized trial that uses machine learning and historical data to achieve a higher probability of success with a smaller number of patients.
Unlearn is partnering with leading pharma companies, including Merck KGaA, Darmstadt, Germany, and continues to have discussions with regulators. Ahead of the Series B, the company announced a multi-year collaboration with Merck KGaA, Darmstadt, Germany which is using TwinRCTs™ to incorporate prognostic information from digital twins into its randomized controlled trials. This will allow Merck KGaA, Darmstadt, Germany to enable smaller control groups and generate evidence suitable for supporting regulatory decisions in its immunology pipeline.
FinSMEs
20/04/2022